Showing results (41-50 of 64) with videos related to
Sort By:
Pageof 7
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.The Lancet. Oncology|October 18, 2016
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyCorey J Langer, Shirish M Gadgeel, Hossein Borghaei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.Cancer|March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptorGlenwood D Goss, Everett E Vokes, Michael S Gordon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studyStephen I Shibata, Vincent Chung, Timothy W Synold, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung CancerShirish M Gadgeel, Alice T Shaw, Ramaswamy Govindan, et al.Journal for Immunotherapy of Cancer|July 18, 2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Julie R Brahmer, Ramaswamy Govindan, Robert A Anders, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.Pageof 7